Skip to main content

Samsung Biologics

Samsung Biologics Co., Ltd. is a leading global contract development and manufacturing organization headquartered in South Korea that provides comprehensive biopharmaceutical production services. The company operates as the specialized biopharmaceutical arm of Samsung Group, offering end-to-end manufacturing solutions ranging from early cell line development to large-scale commercial production. Its principal service offerings include the contract manufacturing of monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and recombinant vaccines for global clients. Samsung Biologics' main revenue drivers stem from long-term manufacturing service agreements and partnership contracts executed with major international pharmaceutical and biotechnology corporations. As an industry leader in biopharmaceutical contract manufacturing, the company holds a dominant market position within the global biopharmaceutical manufacturing and healthcare sector, supporting innovative therapies worldwide. Headquartered in Songdo, Incheon, South Korea, Samsung Biologics is publicly listed and traded with common shares on the Korea Exchange.

26 of the funds FundTelligence covers report a position in Samsung Biologics.

Legal name
Samsung Biologics Co Ltd
Sector
Health Care
Country
South Korea
Funds holding it
26

Funds holding Samsung Biologics

Showing the 8 largest of 26 funds holding it.

Loading...